Welcome to our dedicated page for GeneDx Holdings SEC filings (Ticker: WGS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The GeneDx Holdings Corp. (WGS) SEC filings page on Stock Titan provides access to the company’s public disclosures filed with the U.S. Securities and Exchange Commission. GeneDx is a Delaware‑incorporated company whose Class A common stock trades on The Nasdaq Stock Market under the symbol WGS, with related warrants trading under WGSWW, as noted in its current reports on Form 8‑K.
Investors and analysts can use this page to review current reports on Form 8‑K, which for GeneDx have included announcements of quarterly financial results, updated guidance, and significant corporate events such as board appointments and annual meeting outcomes. These filings offer detail on revenue composition, exome and genome test volumes, margin metrics, cash position, and shareholder voting results, as described in the company’s earnings‑related 8‑K filings.
Because GeneDx positions itself as a global leader in rare disease diagnosis and rare disease genomics, its periodic and current reports are a key source for understanding how its genomic testing business, GeneDx Infinity dataset, and related initiatives translate into financial performance and corporate governance decisions. Filings also disclose information about securities such as its warrants, including listing details and exercise price.
On Stock Titan, SEC documents are paired with AI‑powered summaries that help explain the contents of lengthy filings in accessible language. Users can quickly see the main points from GeneDx’s 8‑K disclosures, and, where applicable, locate information related to quarterly and annual reporting, capital structure, and significant events affecting WGS shareholders. Real‑time updates from EDGAR ensure that new GeneDx filings appear promptly, while AI‑generated highlights make it easier to navigate complex regulatory documents.
A holder of WGS Class A common stock filed a notice of intent to sell 9,374 shares under Rule 144. The shares have an aggregate market value of 929900 and are part of 28,904,590 shares outstanding. The planned sale date is approximately 02/02/2026 on NASDAQ through Morgan Stanley Smith Barney.
The seller acquired the 9,374 shares of Class A common stock on 01/14/2025 as compensation in the form of restricted stock units from the issuer, with compensation as the nature of payment. The signer represents they are not aware of undisclosed material adverse information about the issuer’s operations.
GeneDx Holdings Corp. chief financial officer Kevin Feeley reported routine equity compensation activity involving restricted stock units (RSUs) and related share sales. On January 29, 2026, 754 RSUs converted into the same number of Class A Common shares for no cash consideration.
On the same date, Feeley sold 315 shares at $94 and 2 shares at $92.0601. The company states these sales were made solely to cover tax withholding obligations through a “sell to cover” arrangement and were not discretionary trades. After these transactions, Feeley directly held 9,168 Class A Common shares, plus RSUs representing up to 112,750 shares and options for up to 25,906 shares, all vesting according to their existing schedules.
GeneDx Holdings Corp.'s chief executive officer Katherine Stueland reported routine equity activity tied to restricted stock units. On January 29, 2026 she settled 3,874 RSUs into the same number of Class A common shares for no cash cost, then sold 1,653 shares at a weighted average price of $93.9957 to cover tax withholding obligations through a non‑discretionary “sell to cover” transaction. After these moves she directly owned 16,458 Class A shares, along with RSUs representing contingent rights to receive up to 411,494 additional shares and options to purchase up to 107,610 shares, which vest according to their existing schedules.
A Form 144 notice shows a planned insider sale of 24,155 shares of Class A common stock, with an aggregate market value of $2,369,700. The shares are expected to be sold on or about 01/29/2026 on NASDAQ through Morgan Stanley Smith Barney.
The securities were acquired as compensation in the form of restricted stock units and performance-based restricted stock units on several dates between 2022 and 2025. The document also lists recent sales by Kevin Feeley over the past three months, including blocks such as 3,855 shares on 12/16/2025 for gross proceeds of $554,632.
WGS insider Katherine Stueland has filed a notice of proposed sale of 94,495 shares of Class A common stock through broker Morgan Stanley Smith Barney on NASDAQ. The filing lists an aggregate market value of
The shares to be sold were acquired as equity compensation, including restricted stock units and performance-based restricted stock units granted between
GeneDx Holdings Corp. filed a report stating that it issued a press release on January 12, 2026 outlining its expectations for preliminary, unaudited revenue for the fourth quarter and full year 2025. The update also covers exome and genome test result volumes, GAAP and adjusted gross margin for the same periods, and levels of cash, cash equivalents, marketable securities and restricted cash as of December 31, 2025.
The company additionally provided full year 2026 guidance and released an investor presentation prepared for the 44th Annual J.P. Morgan Healthcare Conference. These materials are furnished as exhibits and are not deemed filed for liability purposes under the securities laws or automatically incorporated into other regulatory documents.
GeneDx Holdings Corp. Chief Financial Officer insider transaction shows routine equity compensation activity. On December 16, 2025, the CFO exercised 7,197 restricted stock units (RSUs), receiving the same number of Class A common shares for no cash consideration. On the same date, multiple small blocks of Class A common stock were sold at weighted average prices between $138.93 and $150.75 per share.
According to the disclosure, these sales were made solely to cover tax withholding obligations arising from the RSU vesting under a “sell to cover” arrangement and were not discretionary trades by the executive. After these transactions, the CFO beneficially owned 8,731 shares of Class A common stock, as well as RSUs representing contingent rights to receive up to 113,504 shares and options to purchase up to 25,906 shares of Class A common stock, all vesting according to their existing terms.
GeneDx Holdings Corp.’s chief executive officer and director reported routine equity transactions involving Class A Common Stock on December 16, 2025. The filing shows 18,750 restricted stock units converting into the same number of shares at an exercise price of $0, increasing the executive’s directly held stock before related sales.
On the same date, the executive sold multiple small blocks of shares at weighted average prices reported between $138.93 and $150.75. According to the notes, these trades were made solely to cover tax withholding obligations tied to the RSU vesting and were not discretionary sales. After these transactions, the executive directly owned 14,237 shares of Class A Common Stock, plus RSUs representing up to 415,368 shares and options to purchase up to 107,610 shares, all vesting over time under their existing award terms.
GeneDx Holdings Corp. reported that its chief financial officer completed an equity award transaction involving Class A Common Stock on 12/09/2025. The filing shows 2,462 restricted stock units were converted into an equal number of shares at $0 exercise price, reflecting the vesting of previously granted RSUs.
To cover tax withholding triggered by this vesting, the officer sold 1,266 shares at $159.28 per share in a "sell to cover" transaction, described as non-discretionary. After these transactions, the officer beneficially owned 5,389 shares of Class A Common Stock, along with RSUs representing up to 120,701 additional shares and options for up to 25,906 shares, all subject to their vesting terms.
GeneDx Holdings Corp. (WGS) director reports insider share sales. A reporting person serving as a director filed a Form 4 for multiple sales of GeneDx Class A common stock on 11/24/2025. The trades were executed indirectly through investment entities Kariba LLC, Rugu2 LLC and VAAL Investment Partners Q9 LP, where the director has voting and investment power.
The sales occurred in several blocks at weighted average prices ranging from about $157.80 to $162.175 per share, with each block reported separately. After the reported transactions, the filing shows continued indirect beneficial ownership of GeneDx Class A shares by each of the three entities. The director disclaims beneficial ownership of these securities except to the extent of any pecuniary interest.